WallStSmart

Equinix Inc (EQIX)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Equinix Inc generates 187% more annual revenue ($9.26B vs $3.22B). WST leads profitability with a 16.9% profit margin vs 14.6%. WST appears more attractively valued with a PEG of 2.91. WST earns a higher WallStSmart Score of 67/100 (B-).

EQIX

Buy

50

out of 100

Grade: C-

Growth: 6.7Profit: 6.5Value: 2.0Quality: 3.5
Piotroski: 3/9Altman Z: 0.55

WST

Strong Buy

67

out of 100

Grade: B-

Growth: 7.3Profit: 8.0Value: 2.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EQIXSignificantly Overvalued (-38.5%)

Margin of Safety

-38.5%

Fair Value

$626.41

Current Price

$1082.83

$456.42 premium

UndervaluedFair: $626.41Overvalued
WSTSignificantly Overvalued (-33.5%)

Margin of Safety

-33.5%

Fair Value

$184.38

Current Price

$297.59

$113.21 premium

UndervaluedFair: $184.38Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EQIX3 strengths · Avg: 8.3/10
Market CapQuality
$106.79B9/10

Large-cap with strong market position

Operating MarginProfitability
21.5%8/10

Strong operational efficiency at 21.5%

EPS GrowthGrowth
22.9%8/10

Earnings expanding 22.9% YoY

WST4 strengths · Avg: 9.0/10
EPS GrowthGrowth
56.1%10/10

Earnings expanding 56.1% YoY

Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.7%8/10

Strong operational efficiency at 21.7%

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

EQIX4 concerns · Avg: 2.5/10
Debt/EquityHealth
1.613/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.912/10

Expensive relative to growth rate

P/E RatioValuation
74.6x2/10

Premium valuation, high expectations priced in

WST2 concerns · Avg: 3.0/10
P/E RatioValuation
39.0x4/10

Premium valuation, high expectations priced in

PEG RatioValuation
2.912/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : EQIX

The strongest argument for EQIX centers on Market Cap, Operating Margin, EPS Growth.

Bull Case : WST

The strongest argument for WST centers on EPS Growth, Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : EQIX

The primary concerns for EQIX are Debt/Equity, Piotroski F-Score, PEG Ratio. A P/E of 74.6x leaves little room for execution misses. Debt-to-equity of 1.61 is elevated, increasing financial risk.

Bear Case : WST

The primary concerns for WST are P/E Ratio, PEG Ratio.

Key Dynamics to Monitor

EQIX profiles as a value stock while WST is a growth play — different risk/reward profiles.

WST carries more volatility with a beta of 1.15 — expect wider price swings.

WST is growing revenue faster at 21.0% — sustainability is the question.

WST generates stronger free cash flow (47M), providing more financial flexibility.

Bottom Line

WST scores higher overall (67/100 vs 50/100), backed by strong 16.9% margins and 21.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Equinix Inc

REAL ESTATE · REIT - SPECIALTY · USA

Equinix, Inc. is an American multinational company headquartered in Redwood City, California, that specializes in Internet connection and data centers.

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?